Corindus appoints Campbell Rogers to its Board of Directors

121

Since 2012, Rogers has served as chief medical officer of HeartFlow. Prior to joining HeartFlow, he served as chief scientific officer and global head of Research and Development at Cordis, a Johnson & Johnson company, where he was responsible for leading investments and research in cardiovascular devices.

Earlier in his career, as an interventional cardiologist, Rogers was associate professor of Medicine at Harvard Medical School and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital with responsibility for all aspects of catheterisation laboratory clinical practice, education and research.

Rogers has conducted extensive clinical research including serving as principal investigator for numerous interventional cardiology device, diagnostic and pharmacology trials, according to a company release. He has served on editorial boards, as an ad-hoc reviewer of a number of medical journals and as author of over 100 publications and two books. Rogers received a bachelor of arts from Harvard College and a medical degree from Harvard Medical School.

David Handler, president and chief executive officer, says, “It was immediately clear that Rogers exceeds our collective criteria for a board member. His experience running the Cath Lab at Brigham and Women’s Hospital, leading the research and development and investment efforts at Cordis, and currently serving as chief medical officer of HeartFlow, will be incredibly valuable as we seek to drive widespread adoption of robotic-assisted PCI to help improve the lives of patients and physicians. We are excited to have him on board.”

Rogers says, ”Having performed many procedures in the cath lab myself, I understand the importance of this technology, and I look forward to helping the Corindus team execute a solid strategy to expand adoption of its CorPath System and to further develop its future product pipeline.”